Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
March 02 2021 - 8:00AM
Exagen Inc. (Nasdaq: XGN), a leading autoimmune
organization, will release financial results for the quarter and
year ended December 31, 2020 after the market close on Tuesday,
March 16, 2021. Ron Rocca, President and Chief Executive Officer,
and Kamal Adawi, Chief Financial Officer, will host a conference
call to review the Company’s results at 4:30 PM Eastern Time (1:30
PM Pacific Time).
Interested parties may access the conference call by dialing
(877) 407-3982 (U.S.) or (201) 493-6780 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
https://investors.exagen.com/
A replay of the conference call will be available until Tuesday,
March 23, 2021 at 11:59 PM Eastern Time (8:59 PM Pacific Time).
Interested parties may access the replay of the conference call by
dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international)
using passcode 13716870. Additionally, a recording of
the webcast will be available using the link on the Exagen investor
relations website approximately 30 minutes after the call
concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
CONTACTS:
Investors
Westwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
Company Contact
Exagen Inc.Kamal Adawi, Chief Financial
OfficerKAdawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024